Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Low-grade serous ovarian carcinoma (LGSOC) is a rare subtype of ovarian cancer characterized by slow growth and distinct molecular features. According to Qing Wang et al. (2024), LGSOC accounts for approximately 6%–10% of serous ovarian cancers worldwide. As per the low-grade serous ovarian carcinoma epidemiology forecast by Expert Market Research, the growing ovarian cancer patient population and improved diagnosis are expected to support future disease identification and management.
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
Read more about this report - Request a Free Sample
Low Grade Serous Ovarian Carcinoma Epidemiology Forecast Report Coverage
Expert Market Research's “Low Grade Serous Ovarian Carcinoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of low grade serous ovarian carcinoma. It projects the future incidence and prevalence rates of low grade serous ovarian carcinoma cases across various populations. The study covers age, gender, and type as major determinants of the low grade serous ovarian carcinoma population. The report highlights patterns in the prevalence of low grade serous ovarian carcinoma over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of low grade serous ovarian carcinoma in the 8 major markets.
Regions Covered
- United States
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Low Grade Serous Ovarian Carcinoma Understanding: Disease Overview
Low grade serous ovarian carcinoma (LGSOC) is a rare and slow-growing subtype of epithelial ovarian cancer that develops from the ovarian surface epithelium or through the progression of serous borderline tumors. It is characterized by relatively indolent growth but demonstrates resistance to conventional chemotherapy compared to high-grade serous ovarian carcinoma. LGSOC commonly affects younger women and is frequently associated with mutations in the MAPK signaling pathway, including KRAS, BRAF, and NRAS. The primary histological type is low-grade serous ovarian cancer, distinguished by low cellular atypia and fewer mitotic figures.
Key Report Insights
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Region |
India |
|
High-Risk Population |
Women with serous borderline ovarian tumors, inherited genetic predisposition, and younger adult women |
|
Key Diagnostic Method |
Histopathological examination with immunohistochemistry and molecular testing |
|
Major Risk Factor |
Genetic alterations in the MAPK signaling pathway (KRAS, BRAF, and NRAS mutations) |
|
Major gap in the market |
Delayed diagnosis and limited effectiveness of conventional chemotherapy |
Low Grade Serous Ovarian Carcinoma Epidemiology Perspective
The low grade serous ovarian carcinoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the low grade serous ovarian carcinoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for low grade serous ovarian carcinoma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
According to Qing Wang et al. (2024) and Kentaro Nakayama et al. (2024), low-grade serous ovarian carcinoma (LGSOC) is a rare subtype of epithelial ovarian cancer, accounting for approximately 6%–10% of serous ovarian cancers and less than 5% of all ovarian carcinoma cases. |
|
Gender-Specific Cases of the Disease |
As described by Kentaro Nakayama et al. (2024), LGSOC occurs in women and is generally diagnosed at a younger age than high-grade serous ovarian carcinoma. The disease has been reported across a wide adult female age range. |
|
Age-Specific Cases of the Disease |
As per Kentaro Nakayama et al. (2024), LGSOC is typically diagnosed in younger women, with an average age at diagnosis of 55.5 years, while several studies have reported a median age of 45 years. Cases have been documented in women 19–79 years of age. |
|
Ethnicity-Wise Cases of the Disease |
According to Caretia J. Washington et al. (2024), evaluation of racial and ethnic differences in ovarian cancer survival supports the assessment of epidemiological variations and healthcare disparities across diverse populations. |
|
Mortality and Survival Analysis of the Disease |
Survival outcomes for LGSOC are influenced by disease stage, treatment approach, and long-term disease progression. Mortality and survival analyses remain important for understanding the overall disease burden and patient outcomes. |
Read more about this report - Request a Free Sample
Country-wise Low Grade Serous Ovarian Carcinoma Epidemiology
The low grade serous ovarian carcinoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
According to Pawel Kordowitzki et al. (2025), there were approximately 19,680 new ovarian cancer cases and 12,740 ovarian cancer deaths in the United States in 2024, reflecting the overall burden of ovarian cancer within which LGSOC represents a rare subtype. |
|
Germany |
According to Dorothee Jakob et al. (2023), more than 7,000 women are diagnosed with ovarian cancer annually in Germany, while approximately 5,400 women die from the disease each year. The 5-year relative survival rate ranges from 40% to 50%. |
|
France |
As reported by Institut Curie, ovarian cancer affects more than 5,000 women annually in France, with diagnosis occurring most often around 65 years of age. Most ovarian cancers are epithelial in origin. |
|
Italy |
According to Lucia Mangone et al. (2022), Italy records approximately 5,179 new ovarian cancer cases and 3,336 deaths annually. Ovarian cancer commonly affects women 55–65 years of age, while the 5-year survival rate is 42.7%. |
|
Spain |
Epidemiological assessment in Spain focuses on evaluating disease incidence, prevalence, demographic distribution, and overall disease burden to support healthcare planning and patient management. |
|
United Kingdom |
Epidemiological evaluation in the United Kingdom emphasizes disease incidence, prevalence, age distribution, and survival patterns to improve understanding of the burden associated with LGSOC. |
|
Japan |
According to Takuma Hayashi et al. (2023), serous carcinoma accounts for 39% of ovarian carcinoma cases in Japan. The country also demonstrates a higher prevalence of type 1 ovarian carcinoma and a lower prevalence of type 2 ovarian carcinoma than Europe and the United States. |
|
India |
Epidemiological evaluation in India focuses on understanding disease incidence, prevalence, demographic characteristics, and overall disease burden to support diagnosis, treatment planning, and long-term management of LGSOC. |
Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape
The regional epidemiology landscape for low grade serous ovarian carcinoma continues to face challenges due to its rarity, limited disease awareness, and inconsistent molecular testing across healthcare systems. Delayed diagnosis and inadequate patient stratification often hinder timely treatment selection. Significant opportunities exist in expanding access to genomic profiling, strengthening rare cancer registries, and improving early referral to specialized oncology centers. The growing adoption of precision medicine, increased availability of targeted therapies, and enhanced epidemiological research are expected to improve disease characterization and support more personalized management strategies across major regional markets.
Low Grade Serous Ovarian Carcinoma: Treatment Overview
Low grade serous ovarian carcinoma treatment primarily involves optimal cytoreductive surgery, which remains the cornerstone of disease management for both early- and advanced-stage cases. Adjuvant therapies may include platinum-based chemotherapy, although response rates are generally limited due to the tumor's intrinsic chemoresistance. Hormonal therapies, such as aromatase inhibitors or tamoxifen, are commonly used for recurrent or maintenance treatment. Additionally, targeted therapies, particularly MEK inhibitors, have emerged as promising options for patients with recurrent disease. Targeted therapy continues to transform the treatment landscape by improving disease control in selected patients.
Key Questions Answered
- What is the current and projected burden of low grade serous ovarian carcinoma across the 8 major markets?
- Which countries across the 8 major markets account for the highest low grade serous ovarian carcinoma patient populations and fastest growth rates?
- What is the diagnosed versus undiagnosed patient population of low grade serous ovarian carcinoma across key countries in the 8 major markets?
- Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of low grade serous ovarian carcinoma across the 8 major markets?
- What are the major drivers contributing to the increasing burden of low grade serous ovarian carcinoma across the 8 major markets?
- How do major comorbidities and risk factors influence low grade serous ovarian carcinoma epidemiology trends across the 8 major markets?
- What are the regional trends in advanced disease progression, treatment uptake, and patient management of low grade serous ovarian carcinoma across the 8 major markets?
- Which patient segments represent the highest unmet clinical need in the low grade serous ovarian carcinoma landscape across the 8 major markets?
- Which therapeutic areas linked to low grade serous ovarian carcinoma are expected to witness the strongest growth opportunities across the 8 major markets?
- How is the low grade serous ovarian carcinoma epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
- Which countries across the 8 major markets offer the most attractive market opportunities based on low grade serous ovarian carcinoma epidemiology and healthcare infrastructure?
- Which epidemiological trends are expected to influence future drug development and market access strategies for low grade serous ovarian carcinoma across the 8 major markets?
Scope of the Low Grade Serous Ovarian Carcinoma Epidemiology Report
- The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of low grade serous ovarian carcinoma based on several factors.
- Low Grade Serous Ovarian Carcinoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
- The low grade serous ovarian carcinoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.
Related Reports
Ovarian Cancer Diagnostics And Therapeutics Market
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$2999 $2699
-
$4399 $3739
-
$5799 $4929
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 2,999
USD 2,699
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,399
USD 3,739
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,799
USD 4,929
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
